OTC Markets Group Welcomes Thiogenesis Therapeutics, Corp. to OTCQX

Rhea-AI Summary

OTC Markets Group (OTCQX: OTCM) has announced that Thiogenesis Therapeutics Corp. (TSX-V: TTI; OTCQX: TTIPF), a clinical-stage biotech company, has qualified to trade on the OTCQX® Best Market, upgrading from the Pink® market. The company began trading on February 12, 2025, under the symbol 'TTIPF'.

The upgrade to OTCQX provides U.S. investors with access to current financial disclosure and Real-Time Level 2 quotes through www.otcmarkets.com. Companies listed on qualified international exchanges can utilize their home market reporting standards while meeting OTCQX's high financial standards, corporate governance practices, and securities law compliance requirements.

Positive

• Upgrade from Pink to OTCQX market indicates higher trading standards and transparency
• Enhanced visibility and accessibility for U.S. investors through Level 2 quotes
• Simplified reporting requirements through home market reporting standards

Negative

• None.

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Thiogenesis Therapeutics Corp. (TSX-V: TTI; OTCQX: TTIPF), a clinical-stage biotech company, has qualified to trade on the OTCQX® Best Market. Thiogenesis Therapeutics Corp. upgraded to OTCQX from the Pink® market.

Thiogenesis Therapeutics Corp. begins trading today on OTCQX under the symbol “TTIPF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance and demonstrate compliance with applicable securities laws.

About Thiogenesis Therapeutics Corp.

Thiogenesis Therapeutics, Corp., is a clinical-stage biopharmaceutical company operating through its wholly owned subsidiary based in San Diego, CA. Thiogenesis is developing sulfur-containing prodrugs that act as precursors to previously approved thiol compounds, with the potential to treat serious pediatric diseases with unmet medical needs. Prodrugs are drugs that contain previously approved active ingredients and are modified so that they only become active when metabolized. For regulatory purposes prodrugs can use existing third-party safety data in regulatory submissions in the streamlined 505 (b)(2) regulatory pathway in the US, and its equivalent hybrid system in Europe, to proceed into human efficacy trials with regulatory clearance. Prodrugs may enhance the profile of the active ingredient to increase its bioavailability and reduce side effects. The Company’s initial target indications include Mitochondrial Encephalopathy Lactic Acidosis and Stroke (“MELAS”), Leigh’s syndrome, Rett syndrome and pediatric MASH.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our three public markets: OTCQX^® Best Market, OTCQB^® Venture Market and Pink^® Open Market.

Our OTC Link^® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN and OTC Link NQB are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Subscribe to the OTC Markets RSS Feed

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

FAQ

When did Thiogenesis Therapeutics (TTIPF) begin trading on OTCQX?

Thiogenesis Therapeutics began trading on the OTCQX Best Market on February 12, 2025, under the symbol TTIPF.

What are the requirements for Thiogenesis to maintain OTCQX listing?

To maintain OTCQX listing, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws.

How does the OTCQX upgrade benefit U.S. investors in Thiogenesis (TTIPF)?

The upgrade provides U.S. investors with access to transparent trading, current financial disclosures, and Real-Time Level 2 quotes through www.otcmarkets.com.

What markets does Thiogenesis Therapeutics trade on after the OTCQX upgrade?

Thiogenesis Therapeutics trades on both the TSX Venture Exchange (TSX-V: TTI) and the OTCQX Best Market (OTCQX: TTIPF).